• Je něco špatně v tomto záznamu ?

Isolated Silymarin Flavonoids Increase Systemic and Hepatic Bilirubin Concentrations and Lower Lipoperoxidation in Mice

J. Šuk, J. Jašprová, D. Biedermann, L. Petrásková, K. Valentová, V. Křen, L. Muchová, L. Vítek,

. 2019 ; 2019 (-) : 6026902. [pub] 20190212

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19027705

Grantová podpora
NV16-27317A MZ0 CEP - Centrální evidence projektů

Bilirubin is considered to be one of the most potent endogenous antioxidants in humans. Its serum concentrations are predominantly affected by the activity of hepatic bilirubin UDP-glucuronosyl transferase (UGT1A1). Our objective was to analyze the potential bilirubin-modulating effects of natural polyphenols from milk thistle (Silybum marianum), a hepatoprotective herb. Human hepatoblastoma HepG2 cells were exposed to major polyphenolic compounds isolated from milk thistle. Based on in vitro studies, 2,3-dehydrosilybins A and B were selected as the most efficient compounds and applied either intraperitoneally or orally for seven days to C57BL/6 mice. After, UGT1A1 mRNA expression, serum, intrahepatic bilirubin concentrations, and lipoperoxidation in the liver tissue were analyzed. All natural polyphenols used increased intracellular concentration of bilirubin in HepG2 cells to a similar extent as atazanavir, a known bilirubinemia-enhancing agent. Intraperitoneal application of 2,3-dehydrosilybins A and B (the most efficient flavonoids from in vitro studies) to mice (50 mg/kg) led to a significant downregulation of UGT1A1 mRNA expression (46 ± 3% of controls, p < 0.005) in the liver and also to a significant increase of the intracellular bilirubin concentration (0.98 ± 0.03vs.1.21 ± 0.02 nmol/mg, p < 0.05). Simultaneously, a significant decrease of lipoperoxidation (61 ± 2% of controls, p < 0.005) was detected in the liver tissue of treated animals, and similar results were also observed after oral treatment. Importantly, both application routes also led to a significant elevation of serum bilirubin concentrations (125 ± 3% and 160 ± 22% of the controls after intraperitoneal and oral administration, respectively, p < 0.005 in both cases). In conclusion, polyphenolic compounds contained in silymarin, in particular 2,3-dehydrosilybins A and B, affect hepatic and serum bilirubin concentrations, as well as lipoperoxidation in the liver. This phenomenon might contribute to the hepatoprotective effects of silymarin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19027705
003      
CZ-PrNML
005      
20190823134326.0
007      
ta
008      
190813s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2019/6026902 $2 doi
035    __
$a (PubMed)30891115
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šuk, Jakub $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Kateřinská 32, Praha 2 12000, Czech Republic.
245    10
$a Isolated Silymarin Flavonoids Increase Systemic and Hepatic Bilirubin Concentrations and Lower Lipoperoxidation in Mice / $c J. Šuk, J. Jašprová, D. Biedermann, L. Petrásková, K. Valentová, V. Křen, L. Muchová, L. Vítek,
520    9_
$a Bilirubin is considered to be one of the most potent endogenous antioxidants in humans. Its serum concentrations are predominantly affected by the activity of hepatic bilirubin UDP-glucuronosyl transferase (UGT1A1). Our objective was to analyze the potential bilirubin-modulating effects of natural polyphenols from milk thistle (Silybum marianum), a hepatoprotective herb. Human hepatoblastoma HepG2 cells were exposed to major polyphenolic compounds isolated from milk thistle. Based on in vitro studies, 2,3-dehydrosilybins A and B were selected as the most efficient compounds and applied either intraperitoneally or orally for seven days to C57BL/6 mice. After, UGT1A1 mRNA expression, serum, intrahepatic bilirubin concentrations, and lipoperoxidation in the liver tissue were analyzed. All natural polyphenols used increased intracellular concentration of bilirubin in HepG2 cells to a similar extent as atazanavir, a known bilirubinemia-enhancing agent. Intraperitoneal application of 2,3-dehydrosilybins A and B (the most efficient flavonoids from in vitro studies) to mice (50 mg/kg) led to a significant downregulation of UGT1A1 mRNA expression (46 ± 3% of controls, p < 0.005) in the liver and also to a significant increase of the intracellular bilirubin concentration (0.98 ± 0.03vs.1.21 ± 0.02 nmol/mg, p < 0.05). Simultaneously, a significant decrease of lipoperoxidation (61 ± 2% of controls, p < 0.005) was detected in the liver tissue of treated animals, and similar results were also observed after oral treatment. Importantly, both application routes also led to a significant elevation of serum bilirubin concentrations (125 ± 3% and 160 ± 22% of the controls after intraperitoneal and oral administration, respectively, p < 0.005 in both cases). In conclusion, polyphenolic compounds contained in silymarin, in particular 2,3-dehydrosilybins A and B, affect hepatic and serum bilirubin concentrations, as well as lipoperoxidation in the liver. This phenomenon might contribute to the hepatoprotective effects of silymarin.
650    _2
$a zvířata $7 D000818
650    _2
$a bilirubin $x metabolismus $7 D001663
650    _2
$a flavonoidy $x chemie $x izolace a purifikace $x farmakologie $7 D005419
650    _2
$a regulace genové exprese enzymů $x účinky léků $7 D015971
650    _2
$a glukuronosyltransferasa $x genetika $x metabolismus $7 D014453
650    _2
$a hemoxygenasa-1 $x genetika $x metabolismus $7 D051547
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a lidé $7 D006801
650    _2
$a intracelulární prostor $x metabolismus $7 D042541
650    _2
$a peroxidace lipidů $x účinky léků $7 D015227
650    _2
$a játra $x účinky léků $x metabolismus $7 D008099
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a silibinin $x aplikace a dávkování $x farmakologie $7 D000077385
650    _2
$a silymarin $x izolace a purifikace $x farmakologie $7 D012838
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jašprová, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Kateřinská 32, Praha 2 12000, Czech Republic.
700    1_
$a Biedermann, David $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1082, Praha 4 14000, Czech Republic.
700    1_
$a Petrásková, Lucie $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1082, Praha 4 14000, Czech Republic.
700    1_
$a Valentová, Kateřina $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1082, Praha 4 14000, Czech Republic.
700    1_
$a Křen, Vladimír $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1082, Praha 4 14000, Czech Republic.
700    1_
$a Muchová, Lucie $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Kateřinská 32, Praha 2 12000, Czech Republic.
700    1_
$a Vítek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Kateřinská 32, Praha 2 12000, Czech Republic. 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Kateřinská 32, Praha 2 12000, Czech Republic.
773    0_
$w MED00180520 $t Oxidative medicine and cellular longevity $x 1942-0994 $g Roč. 2019, č. - (2019), s. 6026902
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30891115 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823134541 $b ABA008
999    __
$a ok $b bmc $g 1432854 $s 1066165
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 2019 $c - $d 6026902 $e 20190212 $i 1942-0994 $m Oxidative medicine and cellular longevity $n Oxid Med Cell Longev $x MED00180520
GRA    __
$a NV16-27317A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace